Clinical Trial Update: Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating IQP-AS-105 for reducing susceptibility to the common cold and upper respiratory tract infections has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Cold
• Upper Respiratory Tract Infection

Drugs mentioned

• IQP-AS-105

Snippet

Sponsor: InQpharm Group | Conditions: Common Cold, Upper Respiratory Tract Infections | Phase 3 | Status: TERMINATED